Schadendorf, D., Chmielowski, B., Milhem, M. M., Sacco, J. J., Bowles, T. L., Tsai, K. K., … Middleton, M. R. (2023). Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (Vol. 21, pp. 119–120).

Schadendorf, D., B. Chmielowski, M. M. Milhem, J. J. Sacco, T. L. Bowles, K. K. Tsai, G. K. In, et al. “Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study.” In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 21:119–20, 2023.

Schadendorf D, Chmielowski B, Milhem MM, Sacco JJ, Bowles TL, Tsai KK, et al. Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. In: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023. p. 119–20.

Schadendorf, D., et al. “Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study.” JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, vol. 21, 2023, pp. 119–20.

Schadendorf D, Chmielowski B, Milhem MM, Sacco JJ, Bowles TL, Tsai KK, In GK, Munoz-Couselo E, VanderWalde AM, Chesney JA, Michels J, Samson A, Beasley GM, Mahmoud F, Wong K, Wise-Draper TM, Zhu J, Bommareddy PK, Hong W, Hou JW, Middleton MR. Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023. p. 119–120.